LANXESS AG/€LXS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About LANXESS AG
LANXESS AG is a specialty chemicals company headquartered in Cologne, Germany. It operates in the chemical industry, focusing on the production of chemical intermediates, additives, specialty chemicals, and plastics. The company's product segments cater to various sectors, including construction, automotive, agriculture, and consumer goods. Established in 2004, LANXESS was formed through a spinoff from Bayer AG. Its global presence spans over 30 countries, with significant operations in Europe, North America, and Asia. The company emphasizes sustainable practices and innovation in its product development to maintain competitive strengths within its industry.
- Ticker
- €LXS
- Sector
- Materials
- Primary listing
- XETRA
- Employees
- 11,495
- Headquarters
- Cologne, Germany
- Website
- lanxess.com
LANXESS AG Metrics
BasicAdvanced
€1B
-
-€7.75
1.15
€0.10
0.86%
Price and volume
Market cap
€1B
Beta
1.15
52-week high
€22.00
52-week low
€11.04
Average daily volume
537K
Dividend rate
€0.10
Financial strength
Current ratio
1.803
Quick ratio
0.896
Long term debt to equity
0.66
Total debt to equity
0.855
Interest coverage (TTM)
-3.47%
Profitability
EBITDA (TTM)
293
Gross margin (TTM)
19.37%
Net profit margin (TTM)
-12.06%
Operating margin (TTM)
-2.69%
Effective tax rate (TTM)
-24.21%
Revenue per employee (TTM)
€480,000
Management effectiveness
Return on assets (TTM)
-1.11%
Return on equity (TTM)
-17.83%
Valuation
Price to revenue (TTM)
0.181
Price to book
0.29
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
13.008
Free cash flow yield (TTM)
7.69%
Free cash flow per share (TTM)
0.892
Dividend yield (TTM)
0.86%
Forward dividend yield
0.86%
Growth
Revenue change (TTM)
-9.81%
Earnings per share change (TTM)
305.45%
3-year revenue growth (CAGR)
-10.88%
10-year revenue growth (CAGR)
-3.13%
3-year earnings per share growth (CAGR)
-18.22%
10-year earnings per share growth (CAGR)
14.44%
3-year dividend per share growth (CAGR)
-54.33%
10-year dividend per share growth (CAGR)
-16.40%
What the Analysts think about LANXESS AG
Analyst ratings (Buy, Hold, Sell) for LANXESS AG stock.
Analyst projections of the future price of LANXESS AG stock.
Bulls say / Bears say
LANXESS reported Q2 sales up 6.5% year on year and EBITDA before exceptionals up 1.3%, with earnings rising 61.7% from Q1. The company maintained its 2026 EBITDA guidance of €450–550 million. (LANXESS)
The FORWARD! programme had delivered about €150 million of annual savings by end-2025, and further measures are expected to add about €170 million by 2028. These savings could support earnings even if end-market demand stays sluggish. (Investing.com)
LANXESS has opened a laboratory to develop and test iron-based materials for lithium iron phosphate batteries. Its established iron-oxide expertise and growing battery demand offer a potential longer-term source of growth, although the commercial scale is not yet clear. (LANXESS)
LANXESS had a weak start to 2026: Q1 sales fell 13.9% year on year and EBITDA before exceptionals dropped 29.3%. The company cited subdued demand, lower selling prices in some businesses and portfolio effects. (LANXESS)
Scope says persistent chemical-sector overcapacity and growing competition from Asian producers are weighing on LANXESS, and sees demand weakness as partly structural. It expects capacity utilisation to stay below its historical average and a broad recovery to be unlikely over the next one to two years. (Scope Ratings)
LANXESS’s BBB- downgrade also highlights financial risk: Scope expects adjusted debt/EBITDA to remain around 4.0 times in 2026–27 and says weak free cash flow limits the company’s ability to reduce debt organically. Refinancing at higher rates could add pressure over time. (Scope Ratings)
Data summarised monthly by Lightyear AI. Last updated on 28 Oct 2026.
LANXESS AG Financial Performance
Revenues and expenses
LANXESS AG Earnings Performance
Company profitability
Upcoming events
No upcoming events
Funds containing LANXESS AG
AllEURUSDGBP
Fund name | Fund size | €LXS weighting |
|---|---|---|
iShares MDAX€EXS3 | €1.5B | 0.67% |
iShares MDAX€EXID | €34M | 0.67% |
Xtrackers S&P 500 Swap£XSPX | $9.7B | 0.21% |
Xtrackers MSCI Europe Small Cap£XXSC | $3.6B | 0.08% |
Xtrackers MSCI Europe Small Cap€DX2J | $3.6B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.